HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: gut.2008.150722v1 57/9/1222    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Hyun, E Articles by Vergnolle, N PubMed PubMed Citation Articles by Hyun, E Articles by Vergnolle, N Topic Collections Relevant Article

Protease-activated receptor-2 activation: a major actor in intestinal inflammation

¹ Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Canada
² Johnson & Johnson Pharmaceutical Research & Development, Spring House Pennsylvania, USA
³ Department of Dermatology and Interdisciplinary Center for Clinical Research, Münster, University of Münster, Germany
⁴ INSERM, U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
⁵ Université Toulouse III Paul Sabatier, Toulouse, France

Correspondence to:
Dr N Vergnolle, INSERM U563, BP 3028, CHU Purpan, 31024 Toulouse Cedex, France; nathalie.vergnolle{at}inserm.fr

Background and aims: The role of protease-activated receptor-2 (PAR₂) during intestinal inflammation is still unclear due to the fact that PAR₂-activating peptide has both pro- and anti-inflammatory properties. The aim of this study was to investigate the effects of PAR₂ deficiency (using PAR₂-deficient mice, PAR₂^–/–) in models of colitis, in order to elucidate the role of endogenous PAR₂ in the process of inflammation in the gut.

Methods: Colonic inflammation in wild-type and PAR₂^–/– mice was induced by dextran sodium sulfate, trinitrobenzene sulfonic acid (TNBS), a T helper-1 predominant model, or oxazolone, a T helper-2 predominant model. Leukocyte recruitment, assessed by intravital microscopy, and inflammatory parameters (myeloperoxidase (MPO), macroscopic and microscopic damage) were assessed during the development of colitis. Lastly, the protein levels of cyclooxygenases (COXs) and adhesion molecules (ICAM-1, VCAM-1, alpha-M, alpha-4) were assessed by using western blot analysis.

Results: In all three models of colitis, MPO activity, macroscopic damage score and bowel thickness were significantly lower in PAR₂^–/– mice. Changes in vessel leukocyte recruitment parameters (rolling and adhesion) were also significantly reduced in PAR₂^–/– mice compared to wild-type mice after the induction of colitis. The protein expression of ICAM-1, VCAM-1 and alpha-4 was significantly attenuated, whereas the expression of COX-1 was significantly increased in PAR₂^–/– mice challenged with TNBS-induced colitis.

Conclusions: The role of endogenous PAR₂ in the gut is pro-inflammatory and independent of the T helper-1 or -2 cytokine profile. Endogenous PAR₂ activation controls leukocyte recruitment in the colon and thus appears as a new potential therapeutic target for the treatment of inflammatory bowel disease.

This article has been cited by other articles:

				R. Spiller The year in Gut 2008 Gut, December 1, 2008; 57(12): 1637 - 1638. [Full Text] [PDF]

				L. R. Gardell, J.-N. Ma, J. G. Seitzberg, A. E. Knapp, H. H. Schiffer, A. Tabatabaei, C. N. Davis, M. Owens, B. Clemons, K. K. Wong, et al. Identification and Characterization of Novel Small-Molecule Protease-Activated Receptor 2 Agonists J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 799 - 808. [Abstract] [Full Text] [PDF]